Stricter screening guidance – The 2024 ACC/AHA PAD guideline urges wider use of automated ABI + PVR in high-risk adults. acc.org
AI regulation is maturing – FDA released draft lifecycle guidance for AI-enabled device software in 2025. fda.gov
Reimbursement is shifting – New Remote Patient Monitoring (RPM) codes (99453, 99454, 99457) give clinics another billing on-ramp for physiologic data. thoroughcare.net
To keep your clinic future-proof, HealthWright Technologies Inc is publishing its multi-year CMAT Advantage roadmap so you can align capital planning and workflow design well ahead of time.
2 | Roadmap at a Glance
Release Window
Code Name
Key Physician Benefits
2025 · Q3
v5.4 “Cassini”
AI-driven PAD risk scores, central-aortic-pressure (CAP) algorithm, single-tap FHIR® export
2025 · Q4
CMAT-RPM Lite
Passive data upload for CPT 99453/99454 billing; automatic clinician-time tracker for 99457
Automatic Time Tracking: On-platform stopwatch logs > 20 min interactive time for CPT 99457. ♪thoroughcare.net
Alert Rules Engine: Flags rapid ankle-pressure drops or HRV shifts for same-day callbacks.
4 | Medium-Term (2026) Milestones
Feature
Physician Impact
v6.0 “Atlas”
• Surrogate 12-lead (3-wire VCG) overlays PAD & ANS findings for holistic cardio-metabolic view.• Home-ankle cuff pairs via Bluetooth to reduce in-office repeat testing.• Zero-trust security meets evolving FDA cybersecurity pre-market guidance.
Data-Hub 2.0
• Multi-location benchmarking—see which site is leaving CPT dollars unclaimed.• Bulk export for MIPS CQM #418 (screening for psychosocial risk), PAD quality metrics.
5 | Long-Term Vision (2027 – 2028)
Predictive Analytics “Nova” Platform
Uses de-identified cross-practice datasets to forecast 12-month PAD progression.
Offers pay-for-performance dashboards for VBC contracts.
Patient Portal & Tele-Expert API
Patients access color-coded trends; can forward to vascular specialists.
Clinics bill interprofessional e-consult CPT 99451 without new hardware.
Expandable Sensor Bus
Hardware headroom to snap-in photoplethysmography (PPG) finger sensors or skin-temperature probes as reimbursement pathways mature.
6 | Compliance & Regulatory Alignment
Rule / Draft Guidance
Roadmap Alignment
FDA AI-Enabled Device Lifecycle Draft (Jan 2025)
Adopts pre-determined change-control plan (PCCP) for AI modules starting v5.4. fda.gov
Assessing Autonomic Dysfunction in Sleep Disorders with the CMAT Advantage™ System: A New Era in Sleep Medicine The relationship between autonomic regulation and sleep quality is deeply intertwined. Patients with obstructive sleep apnea (OSA) or chronic insomnia often exhibit heightened sympathetic tone, reduced HRV, and vascular reactivity. These parameters, once invisible to standard sleep testing,…
The Future of Autonomic & Vascular Screening Preventive diagnostics are transitioning from reactive care to data-driven early detection. The TM-Flow System exemplifies this evolution—combining vascular, autonomic and neuropathic assessment in one test. Role of Technology Advances in sensors and AI are reshaping screening. Devices like TM-Flow generate actionable physiological data within minutes, supporting tele-review and…
Introduction Even well-intended diagnostic purchases can under-deliver when they clash with day-to-day clinical realities—think inconsistent results, stalled workflows, or reimbursement headaches. Drawing on thousands of support tickets and field implementations, HealthWright Technologies Inc has identified five pitfalls that routinely erode return on investment. Here’s how the CMAT Advantage—our flagship CMAT device for PAD, autonomic-nerve, and…
1. Why a Strategic Buying Process Matters Value-based care, shrinking reimbursements, and tight capital budgets require proof that every device improves outcomes and the bottom line. HealthWright Technologies Inc positions the CMAT Advantage as a partnership, bundling FDA-cleared hardware with onboarding, billing resources, and business-performance analytics so physicians recoup their investment quickly and predictably. 2….
1. The Evolving Landscape of PAD Screening Peripheral arterial disease (PAD) affects nearly 20 million U.S. adults, yet fewer than half are diagnosed before symptoms such as claudication appear.¹ Most clinics still depend on: Recent studies reveal sensitivity gaps in diabetic or calcified vessels and workflow bottlenecks that suppress case-finding. In response, HealthWright Technologies Inc…